BioArctic AB’s Partner Eisai Announces Approval of Leqembi® (樂意保®) for Alzheimer’s Disease Treatment in Hong Kong

BioArctic AB  is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...

July 11, 2024 | Thursday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
Biocytogen Pharmaceuticals Announces Antibody Evaluation and Option Agreement with Gilead Sciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315)  announces an antibody evaluation and option agreement with Gil...

February 20, 2024 | Tuesday | News
HUTCHMED & Inmagene Advance, License Drug Candidates IMG-007 and IMG-004

Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...

February 02, 2024 | Friday | News
HUTCHMED Granted ELUNATE® Approval in Hong Kong for Metastatic Colorectal Cancer Treatment

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong&...

January 30, 2024 | Tuesday | News
China's RemeGen's RC88 earns FDA Fast Track, heralding new hope for ovarian cancer patients

RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently dev...

January 15, 2024 | Monday | News
Everest Medicines' Nefecon® NDA Accepted in Taiwan for Adult Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...

December 27, 2023 | Wednesday | News
Merck Boosts Oncology Portfolio with Commercialization Agreement for Phase III Asset Pimicotinib from Abbisko

Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) Merck to receive an exclusive commercial license ...

December 05, 2023 | Tuesday | News
Everest Medicines Secures Taiwan Approval for XERAVA® in Treating Complicated Intra-Abdominal Infections in Adults

"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...

September 28, 2023 | Thursday | News
HUTCHMED Completes Patient Enrollment for Tazemetostat Study in Chinese Follicular Lymphoma

The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...

September 12, 2023 | Tuesday | News
Bristol Myers Squibb Signs $50M Deal to Address Immune-Mediated Diseases in Asia

US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...

September 07, 2023 | Thursday | News
Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...

August 15, 2023 | Tuesday | News
HUTCHMED's Fruquintinib Combo Receives Breakthrough Designation in China for Advanced Endometrial Cancer, Enrollment Complete

It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...

July 20, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in